Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 2;17(11):3907-3912.
doi: 10.1080/21645515.2021.1951097. Epub 2021 Jul 19.

Participating in a vaccine trial for COVID-19 in Senegal: trust and information

V Ridde  1   2 , M F Ba  2 , I Gaye  2 , A I Diallo  2 , E Bonnet  3 , A Faye  2
Affiliations

Participating in a vaccine trial for COVID-19 in Senegal: trust and information

V Ridde et al. Hum Vaccin Immunother. .

Abstract

This research aims to understand the level and determinants of people's willingness to participate in a vaccine trial for COVID-19 in Senegal. We conducted a telephone survey among a marginal quota sample of 607 people over 18 years of age. Only 44.3% of the participants wanted to participate in a vaccine trial for COVID-19, with females intending to participate more than males (AOR = 1.82, 95% CI [1.22-2.72]). Participants who intended to be vaccinated against COVID-19 (AOR = 6.48, 95% CI [4.12-10.4]) and who thought that being infected with the coronavirus would have a significant impact on their health (AOR = 2.34, 95% CI [1.57, 3.51]) were more likely to agree to take part in the COVID-19 vaccine trial. Confidence in the vaccine, health personnel, and the government in the fight against the pandemic are key factors in participants' willingness to participate in a vaccine trial in Senegal.

Keywords: COVID-19; Senegal; Vaccine trial; acceptability; participation.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Reasons for willingness to participate in a COVID-19 vaccine trial (N = 269).
Figure 2.
Figure 2.
Reasons for refusing to participate in a COVID-19 vaccine trial (N = 337).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chabrol F. Biomedicine, public health, and citizenship in the advent of antiretrovirals in Botswana: the advent of antiretrovirals in Botswana. Dev World Bioeth. 2014;14:75–82. doi:10.1111/dewb.12051. - DOI - PubMed
    1. Lachenal G. Le médicament qui devait sauver l’Afrique: un scandale pharmaceutique aux colonies. Paris (France): La Découverte; 2014.
    1. Moulin AM, Chabrol F, Ouvrier A. Chapitre 24. Histoire d’un vaccin pas comme les autres : les premiers pas du vaccin contre l’hépatite B au Sénégal. In: Delaunay V, Desclaux A, Sokhna C, editors. Niakhar, mémoires et perspectives. Montpellier (France): IRD Éditions;2018. p. 489–510. doi:10.4000/books.irdeditions.31872. - DOI
    1. Koster W, Ndione AG, Adama M, Guindo I, Sow I, Diallo S, Sakandé J, Ondoa P. An oral history of medical laboratory development in francophone West African countries. Af J Lab Med. 2021;10. doi:10.4102/ajlm.v10i1.1157. - DOI - PMC - PubMed
    1. Ouvrier A. La recherche médicale en Afrique est un moyen pour l’Occident de tester des médicaments dangereux. Des idées reçues en santé mondiale. Montréal (Canada): Presses de l’Université de Montréal. p. 215–18; 2015. doi:10.4000/books.pum.3607 - DOI

Publication types